Nyxoah (NYXH) - EV/EBITDA Multiple

Nyxoah S.A - graphic logo of issuer NYXH

Nyxoah S.A. (NYXH) focuses on independently achieving medical milestones and preparing for US sales, completely ignoring merger and acquisition deals. Expert scientists lead the team, confidently scaling innovations for the fight against apnea to a global level. This price chart featuring the 0.00 metric highlights the business's protection provided by patents and strict FDA oversight.

NYXH Nyxoah, S.A.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/17/2026

Analytical breakdowns for Nyxoah SA (NYXH)

- stock price and consensus target price:
Summary company analysis:Nyxoah S.A (NYXH)
Manufactured products of Nyxoah

High debt leverage makes the business vulnerable to market shocks and loan servicing costs. The implementation of ESG standards and the reduction of material intensity for Nyxoah S.A. neurostimulators create an internal reserve for cost optimization. The EV/EBITDA multiple valuation correlates the total enterprise value with its operating profit before taxes, depreciation, and amortization. Analyzing this trend allows an investor to determine the asset's real value and the sustainability of its cash flow.

Competitors of Nyxoah S.A.

Intuitive Surgical - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio danaher.com (DHR)|BDX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|STE (STERIS PLC) - Enterprise Value to Operating Income Before Depreciation|West Pharma Corp (WST) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BAX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization masimo.com|Stevanato Group (STVN) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Teleflex (TFX)|Enterprise Value to Operating Income Before Depreciation Ratio MMSI|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Envista Holdings Corp NVST|Business Value to Operating Income Before Depreciation ICUI|XRAY: Enterprise Value to EBITDA Ratio|LMAT - EV/EBITDA Multiple|AtriCure Inc (ATRC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio STAAR Surgical|NAGE (niagenbioscience.com) - EV/EBITDA Multiple|Company Value to EBITDA ZimVie Corp ZIMV|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AngioDynamics (ANGO)|Cerus - Enterprise Value to Operating Income Before Depreciation|Alpha Teknova, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio MGRM (Monogram Technologies Inc.)|STSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio infusystem.com INFU|UTMD (Utah Med) - Enterprise Value to EBITDA Ratio|KORU Medical Systems Inc. (KRMD) - EV/EBITDA Multiple|MBOT (Microbot Medical, Inc.) - EV/EBITDA Multiple|PDEX: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zentek Ltd. (ZTEK)|EV/EBITDA Multiple Elutia Inc. (ELUT)|EV/EBITDA Multiple MLSS (Milestone Scientific Inc)|Enterprise Value to EBITDA Multiple NEXGEL, Inc.|Retractable Technologies, Inc. - EV/EBITDA Multiple|HBIO - EV/EBITDA Multiple|FEMY (femasys.com) - Enterprise Value to EBITDA Ratio|Meihua Medical (MHUA) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio POAI|CJMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATRI|Enterprise Value to Operating Income Before Depreciation Ratio NURO